Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.

pubmed: 32427307 doi: 10.1001/jama.2020.4006

Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382.

pubmed: 28537254 pmcid: 5458077 doi: 10.1038/ncomms15382

Roszkiewicz M, Dopytalska K, Szymanska E, Jakimiuk A, Walecka I. Environmental risk factors and epigenetic alternations in psoriasis. Ann Agric Environ Med. 2020;27(3):335–42.

pubmed: 32955211 doi: 10.26444/aaem/112107

Fry L, Baker BS, Powles AV, Engstrand L. Psoriasis is not an autoimmune disease? Exp Dermatol. 2015;24(4):241–4.

pubmed: 25348334 doi: 10.1111/exd.12572

Arakawa A, Siewert K, Stohr J, Besgen P, Kim SM, Ruhl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015;212(13):2203–12.

pubmed: 26621454 pmcid: 4689169 doi: 10.1084/jem.20151093

Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530.

pubmed: 29425183 pmcid: 5855752 doi: 10.3390/ijms19020530

Cheung KL, Jarrett R, Subramaniam S, Salimi M, Gutowska-Owsiak D, Chen YL, et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med. 2016;213(11):2399–412.

pubmed: 27670592 pmcid: 5068234 doi: 10.1084/jem.20160258

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621.

pubmed: 25470744 doi: 10.1038/ncomms6621

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

pubmed: 19641206 doi: 10.1056/NEJMra0804595

Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS ONE. 2017;12(7): e0181039.

pubmed: 28719618 pmcid: 5515416 doi: 10.1371/journal.pone.0181039

Sundarrajan S, Arumugam M. Comorbidities of psoriasis—exploring the links by network approach. Plos One. 2016;11(3): e0149175.

pubmed: 26966903 pmcid: 4788348 doi: 10.1371/journal.pone.0149175

rob f hj. Komorbidity psoriázy a jejich management. Remedia 2019;1/2019(29):56–60.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65 e19.

pubmed: 29928910 doi: 10.1016/j.jaad.2018.06.027

Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29(5):487–95.

pubmed: 29057684 doi: 10.1080/09546634.2017.1395800

Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–8.

pubmed: 31225638 doi: 10.1111/bjd.18245

Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts. J Allergy Clin Immunol. 2011;127(5):1110–8.

pubmed: 21388665 doi: 10.1016/j.jaci.2011.01.053

Montero-Vilchez T, Cuenca-Barrales C, Martinez-Lopez A, Molina-Leyva A, Arias-Santiago S. Skin adverse events related to personal protective equipment: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(10):1994–2006.

pubmed: 34077565 doi: 10.1111/jdv.17436

Sikora M, Chrabaszcz M, Maciejewski C, Zaremba M, Waskiel A, Olszewska M, et al. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018;45(12):1468–70.

pubmed: 30222202 doi: 10.1111/1346-8138.14647

Stehlikova Z, Kostovcik M, Kostovcikova K, Kverka M, Juzlova K, Rob F, et al. Dysbiosis of skin microbiota in psoriatic patients: co-occurrence of fungal and bacterial communities. Front Microbiol. 2019;10:438.

pubmed: 30949136 pmcid: 6437110 doi: 10.3389/fmicb.2019.00438

Munz OH, Sela S, Baker BS, Griffiths CE, Powles AV, Fry L. Evidence for the presence of bacteria in the blood of psoriasis patients. Arch Dermatol Res. 2010;302(7):495–8.

pubmed: 20607546 doi: 10.1007/s00403-010-1065-0

Ramirez-Bosca A, Navarro-Lopez V, Martinez-Andres A, Such J, Frances R, Horga de la Parte J, et al. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151(6):670–1.

Codoner FM, Ramirez-Bosca A, Climent E, Carrion-Gutierrez M, Guerrero M, Perez-Orquin JM, et al. Gut microbial composition in patients with psoriasis. Sci Rep. 2018;8(1):3812.

pubmed: 29491401 pmcid: 5830498 doi: 10.1038/s41598-018-22125-y

Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11(1):43–9.

pubmed: 15592573 doi: 10.1038/nm1162

Maroto-Morales D, Montero-Vilchez T, Arias-Santiago S. Study of skin barrier function in psoriasis: The impact of emollients. Life (Basel). 2021;11(7).

Montero-Vilchez T, Segura-Fernandez-Nogueras MV, Perez-Rodriguez I, Soler-Gongora M, Martinez-Lopez A, Fernandez-Gonzalez A, et al. Skin barrier function in psoriasis and atopic dermatitis: transepidermal water loss and temperature as useful tools to assess disease severity. J Clin Med. 2021;10(2).

Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:69.

Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8(2):110–20.

pubmed: 21278760 pmcid: 4003137 doi: 10.1038/cmi.2010.67

Yu JJ, Ruddy MJ, Conti HR, Boonanantanasarn K, Gaffen SL. The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. Infect Immun. 2008;76(9):4206–13.

pubmed: 18591228 pmcid: 2519446 doi: 10.1128/IAI.01209-07

O’Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603–9.

pubmed: 19448631 pmcid: 2709990 doi: 10.1038/ni.1736

Tang C, Kakuta S, Shimizu K, Kadoki M, Kamiya T, Shimazu T, et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat Immunol. 2018;19(7):755–65.

pubmed: 29915298 doi: 10.1038/s41590-018-0134-y

Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L519–28.

pubmed: 17071720 doi: 10.1152/ajplung.00312.2006

Dunne A, Ross PJ, Pospisilova E, Masin J, Meaney A, Sutton CE, et al. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol. 2010;185(3):1711–9.

pubmed: 20610650 doi: 10.4049/jimmunol.1000105

Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14(3):275–81.

pubmed: 18264110 pmcid: 2901867 doi: 10.1038/nm1710

Caruso R, Fina D, Paoluzi OA, Del Vecchio BG, Stolfi C, Rizzo A, et al. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol. 2008;38(2):470–8.

pubmed: 18200634 doi: 10.1002/eji.200737635

Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35(4):596–610.

pubmed: 21982596 pmcid: 3205267 doi: 10.1016/j.immuni.2011.08.001

Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186(3):1495–502.

pubmed: 21172868 doi: 10.4049/jimmunol.1001001

Watson AJ, Duckworth CA, Guan Y, Montrose MH. Mechanisms of epithelial cell shedding in the mammalian intestine and maintenance of barrier function. Ann N Y Acad Sci. 2009;1165:135–42.

pubmed: 19538298 doi: 10.1111/j.1749-6632.2009.04027.x

Peltonen S, Riehokainen J, Pummi K, Peltonen J. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis. Br J Dermatol. 2007;156(3):466–72.

pubmed: 17300235 doi: 10.1111/j.1365-2133.2006.07642.x

Richetta AG, Grassi S, Moliterni E, Chello C, Calvieri C, Carnevale R, et al. Increased intestinal barrier permeability in patients with moderate to severe plaque-type psoriasis. J Dermatol. 2020;47(10):e366–8.

pubmed: 32789984 doi: 10.1111/1346-8138.15361

Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS ONE. 2019;14(1): e0210728.

pubmed: 30640940 pmcid: 6331146 doi: 10.1371/journal.pone.0210728

Sikora M, Stec A, Chrabaszcz M, Waskiel-Burnat A, Zaremba M, Olszewska M, et al. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J Clin Med. 2019;8(7):1021.

pubmed: 31336842 pmcid: 6678629 doi: 10.3390/jcm8071021

Sikora M, Chrabaszcz M, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019;33(10):1907–12.

pubmed: 31120609 doi: 10.1111/jdv.15700

Linehan JL, Harrison OJ, Han SJ, Byrd AL, Vujkovic-Cvijin I, Villarino AV, et al. Non-classical immunity controls microbiota impact on skin immunity and tissue repair. Cell. 2018;172(4):784-96 e18.

pubmed: 29358051 pmcid: 6034182 doi: 10.1016/j.cell.2017.12.033

Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature. 2015;520(7545):104–8.

pubmed: 25539086 pmcid: 4667810 doi: 10.1038/nature14052

Chen B, Chen H, Shu X, Yin Y, Li J, Qin J, et al. Presence of segmented filamentous bacteria in human children and its potential role in the modulation of human gut immunity. Front Microbiol. 2018;9:1403.

pubmed: 30008704 pmcid: 6034559 doi: 10.3389/fmicb.2018.01403

Stepankova R, Sinkora J, Hudcovic T, Kozakova H, Tlaskalova-Hogenova H. Differences in development of lymphocyte subpopulations from gut-associated lymphatic tissue (GALT) of germfree and conventional rats: effect of aging. Folia Microbiol (Praha). 1998;43(5):531–4.

pubmed: 9821320 doi: 10.1007/BF02820814

Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–27.

pubmed: 20620945 pmcid: 2904693 doi: 10.1016/j.immuni.2010.06.001

Stepankova R, Powrie F, Kofronova O, Kozakova H, Hudcovic T, Hrncir T, et al. Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis. 2007;13(10):1202–11.

pubmed: 17607724 doi: 10.1002/ibd.20221

Chaonan Sun LC, Huan Yang, Hongjiang Sun, Zhen Xie, Bei Zhao, Xuemei Jiang, Bi Qin, Zhu Shen. Involvement of Gut Microbiota in the Development of Psoriasis Vulgaris. 2020.

Kawashima K, Misawa H, Moriwaki Y, Fujii YX, Fujii T, Horiuchi Y, et al. Ubiquitous expression of acetylcholine and its biological functions in life forms without nervous systems. Life Sci. 2007;80(24–25):2206–9.

pubmed: 17363003 doi: 10.1016/j.lfs.2007.01.059

Masson F, Talon R, Montel MC. Histamine and tyramine production by bacteria from meat products. Int J Food Microbiol. 1996;32(1–2):199–207.

pubmed: 8880339 doi: 10.1016/0168-1605(96)01104-X

Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS ONE. 2012;7(2): e31951.

pubmed: 22384111 pmcid: 3285189 doi: 10.1371/journal.pone.0031951

Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015;39(4):509–21.

pubmed: 25701044 doi: 10.1093/femsre/fuu010

Omenetti S, Pizarro TT. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Immunol. 2015;6:639.

pubmed: 26734006 pmcid: 4681807 doi: 10.3389/fimmu.2015.00639

Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401–12.

pubmed: 7782892 doi: 10.1093/jn/125.6.1401

Wu SE, Hashimoto-Hill S, Woo V, Eshleman EM, Whitt J, Engleman L, et al. Microbiota-derived metabolite promotes HDAC3 activity in the gut. Nature. 2020;586(7827):108–12.

pubmed: 32731255 pmcid: 7529926 doi: 10.1038/s41586-020-2604-2

Schwarz A, Bruhs A, Schwarz T. The short-chain fatty acid sodium butyrate functions as a regulator of the skin immune system. J Invest Dermatol. 2017;137(4):855–64.

pubmed: 27887954 doi: 10.1016/j.jid.2016.11.014

Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461(7268):1282–6.

pubmed: 19865172 pmcid: 3256734 doi: 10.1038/nature08530

Drago F, Ciccarese G, Indemini E, Savarino V, Parodi A. Psoriasis and small intestine bacterial overgrowth. Int J Dermatol. 2018;57(1):112–3.

pubmed: 29057460 doi: 10.1111/ijd.13797

McFadden J, Valdimarsson H, Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol. 1991;125(5):443–7.

pubmed: 1721523 doi: 10.1111/j.1365-2133.1991.tb14769.x

Norrlind R. Psoriasis following infections with hemolytic streptococci. Acta Derm Venereol. 1950;30(1):64–72.

pubmed: 15409831

Perez-Lorenzo R, Zambrano-Zaragoza JF, Saul A, Jimenez-Zamudio L, Reyes-Maldonado E, Garcia-Latorre E. Autoantibodies to autologous skin in guttate and plaque forms of psoriasis and cross-reaction of skin antigens with streptococcal antigens. Int J Dermatol. 1998;37(7):524–31.

pubmed: 9679694 doi: 10.1046/j.1365-4362.1998.00512.x

Sigurdardottir SL, Thorleifsdottir RH, Valdimarsson H, Johnston A. The association of sore throat and psoriasis might be explained by histologically distinctive tonsils and increased expression of skin-homing molecules by tonsil T cells. Clin Exp Immunol. 2013;174(1):139–51.

pubmed: 23750651 pmcid: 3784221 doi: 10.1111/cei.12153

Rudramurthy SM, Honnavar P, Chakrabarti A, Dogra S, Singh P, Handa S. Association of Malassezia species with psoriatic lesions. Mycoses. 2014;57(8):483–8.

pubmed: 24655111 doi: 10.1111/myc.12186

Tomi NS, Kranke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol. 2005;53(1):67–72.

pubmed: 15965423 doi: 10.1016/j.jaad.2005.02.034

Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1(1):31.

pubmed: 24451201 pmcid: 4177411 doi: 10.1186/2049-2618-1-31

Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res. 2012;304(1):15–22.

pubmed: 22065152 doi: 10.1007/s00403-011-1189-x

Tett A, Pasolli E, Farina S, Truong DT, Asnicar F, Zolfo M, et al. Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. NPJ Biofilms Microbiomes. 2017;3:14.

pubmed: 28649415 pmcid: 5481418 doi: 10.1038/s41522-017-0022-5

Bukin YS, Galachyants YP, Morozov IV, Bukin SV, Zakharenko AS, Zemskaya TI. The effect of 16S rRNA region choice on bacterial community metabarcoding results. Sci Data. 2019;6: 190007.

pubmed: 30720800 pmcid: 6362892 doi: 10.1038/sdata.2019.7

Castelino M, Eyre S, Moat J, Fox G, Martin P, Ho P, et al. Optimisation of methods for bacterial skin microbiome investigation: primer selection and comparison of the 454 versus MiSeq platform. BMC Microbiol. 2017;17(1):23.

pubmed: 28109256 pmcid: 5251215 doi: 10.1186/s12866-017-0927-4

Willis C, Desai D, LaRoche J. Influence of 16S rRNA variable region on perceived diversity of marine microbial communities of the Northern North Atlantic. FEMS Microbiol Lett. 2019. https://doi.org/10.1093/femsle/fnz152 .

doi: 10.1093/femsle/fnz152 pubmed: 31344223 pmcid: 6673769

Yang B, Wang Y, Qian PY. Sensitivity and correlation of hypervariable regions in 16S rRNA genes in phylogenetic analysis. BMC Bioinform. 2016;17:135.

doi: 10.1186/s12859-016-0992-y

Conlan S, Kong HH, Segre JA. Species-level analysis of DNA sequence data from the NIH human microbiome project. PLoS ONE. 2012;7(10): e47075.

pubmed: 23071716 pmcid: 3468466 doi: 10.1371/journal.pone.0047075

Jo JH, Kennedy EA, Kong HH. Research techniques made simple: bacterial 16S ribosomal RNA gene sequencing in cutaneous research. J Invest Dermatol. 2016;136(3):e23–7.

pubmed: 26902128 pmcid: 5482524 doi: 10.1016/j.jid.2016.01.005

Meisel JS, Hannigan GD, Tyldsley AS, SanMiguel AJ, Hodkinson BP, Zheng Q, et al. Skin microbiome surveys are strongly influenced by experimental design. J Invest Dermatol. 2016;136(5):947–56.

pubmed: 26829039 pmcid: 4842136 doi: 10.1016/j.jid.2016.01.016

Grice EA, Kong HH, Renaud G, Young AC, Program NCS, Bouffard GG, et al. A diversity profile of the human skin microbiota. Genome Res. 2008;18(7):1043–50.

pubmed: 18502944 pmcid: 2493393 doi: 10.1101/gr.075549.107

Jumpstart Consortium Human Microbiome Project Data Generation Working G. Evaluation of 16S rDNA-based community profiling for human microbiome research. PLoS One. 2012;7(6):e39315.

Teng F, Darveekaran Nair SS, Zhu P, Li S, Huang S, Li X, et al. Impact of DNA extraction method and targeted 16S-rRNA hypervariable region on oral microbiota profiling. Sci Rep. 2018;8(1):16321.

pubmed: 30397210 pmcid: 6218491 doi: 10.1038/s41598-018-34294-x

Paulino LC, Tseng CH, Strober BE, Blaser MJ. Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. J Clin Microbiol. 2006;44(8):2933–41.

pubmed: 16891514 pmcid: 1594634 doi: 10.1128/JCM.00785-06

Takemoto A, Cho O, Morohoshi Y, Sugita T, Muto M. Molecular characterization of the skin fungal microbiome in patients with psoriasis. J Dermatol. 2015;42(2):166–70.

pubmed: 25510344 doi: 10.1111/1346-8138.12739

Jagielski T, Rup E, Ziolkowska A, Roeske K, Macura AB, Bielecki J. Distribution of Malassezia species on the skin of patients with atopic dermatitis, psoriasis, and healthy volunteers assessed by conventional and molecular identification methods. BMC Dermatol. 2014;14:3.

pubmed: 24602368 pmcid: 3975586 doi: 10.1186/1471-5945-14-3

Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol. 2001;39(3):243–51.

pubmed: 11446527 doi: 10.1080/mmy.39.3.243.251

Amaya M, Tajima M, Okubo Y, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in the lesional skin of psoriasis patients. J Dermatol. 2007;34(9):619–24.

pubmed: 17727364 doi: 10.1111/j.1346-8138.2007.00343.x

Chang HW, Yan D, Singh R, Liu J, Lu X, Ucmak D, et al. Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome. 2018;6(1):154.

pubmed: 30185226 pmcid: 6125946 doi: 10.1186/s40168-018-0533-1

Hurabielle C, Link VM, Bouladoux N, Han SJ, Merrill ED, Lightfoot YL, et al. Immunity to commensal skin fungi promotes psoriasiform skin inflammation. Proc Natl Acad Sci U S A. 2020;117(28):16465–74.

pubmed: 32601220 pmcid: 7368261 doi: 10.1073/pnas.2003022117

Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016;7:455.

pubmed: 27065999 pmcid: 4815357 doi: 10.3389/fmicb.2016.00455

Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353(18):1899–911.

pubmed: 16267321 doi: 10.1056/NEJMoa043802

Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, et al. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS ONE. 2012;7(6): e37818.

pubmed: 22719852 pmcid: 3377712 doi: 10.1371/journal.pone.0037818

Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O, Maharshak N. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol. 2019;46(7):595–603.

pubmed: 31141234 doi: 10.1111/1346-8138.14933

Tan L, Zhao S, Zhu W, Wu L, Li J, Shen M, et al. The Akkermansia muciniphila is a gut microbiota signature in psoriasis. Exp Dermatol. 2018;27(2):144–9.

pubmed: 29130553 doi: 10.1111/exd.13463

Reiss Z, Rob F, Kolar M, Schierova D, Kreisinger J, Jackova Z, et al. Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy. Front Cell Infect Microbiol. 2022;12:1064537.

pubmed: 36704107 doi: 10.3389/fcimb.2022.1064537

Yegorov S, Babenko D, Kozhakhmetov S, Akhmaltdinova L, Kadyrova I, Nurgozhina A, et al. Psoriasis is associated with elevated gut IL-1alpha and intestinal microbiome alterations. Front Immunol. 2020;11: 571319.

pubmed: 33117362 pmcid: 7559734 doi: 10.3389/fimmu.2020.571319

Yeh NL, Hsu CY, Tsai TF, Chiu HY. Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment. Clin Drug Investig. 2019;39(12):1195–203.

pubmed: 31549347 doi: 10.1007/s40261-019-00849-7

Demirci M, Tokman HB, Uysal HK, Demiryas S, Karakullukcu A, Saribas S, et al. Reduced Akkermansia muciniphila and Faecalibacterium prausnitzii levels in the gut microbiota of children with allergic asthma. Allergol Immunopathol (Madr). 2019;47(4):365–71.

pubmed: 30765132 doi: 10.1016/j.aller.2018.12.009

Pittayanon R, Lau JT, Leontiadis GI, Tse F, Yuan Y, Surette M, et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology. 2020;158(4):930-46 e1.

pubmed: 31812509 doi: 10.1053/j.gastro.2019.11.294

Eppinga H, Sperna Weiland CJ, Thio HB, van der Woude CJ, Nijsten TE, Peppelenbosch MP, et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016;10(9):1067–75.

pubmed: 26971052 doi: 10.1093/ecco-jcc/jjw070

Fritz JV, Desai MS, Shah P, Schneider JG, Wilmes P. From meta-omics to causality: experimental models for human microbiome research. Microbiome. 2013;1(1):14.

pubmed: 24450613 pmcid: 3971605 doi: 10.1186/2049-2618-1-14

Okada K, Matsushima Y, Mizutani K, Yamanaka K. The role of gut microbiome in psoriasis: oral administration of Staphylococcus aureus and Streptococcus danieliae exacerbates skin inflammation of imiquimod-induced psoriasis-like dermatitis. Int J Mol Sci. 2020;21(9):3303.

pubmed: 32392785 pmcid: 7246652 doi: 10.3390/ijms21093303

Stehlikova Z, Kostovcikova K, Kverka M, Rossmann P, Dvorak J, Novosadova I, et al. Crucial role of microbiota in experimental psoriasis revealed by a gnotobiotic mouse model. Front Microbiol. 2019;10:236.

pubmed: 30846974 pmcid: 6394148 doi: 10.3389/fmicb.2019.00236

Heissigerova J, Seidler Stangova P, Klimova A, Svozilkova P, Hrncir T, Stepankova R, et al. The microbiota determines susceptibility to experimental autoimmune uveoretinitis. J Immunol Res. 2016;2016:5065703.

pubmed: 27294159 pmcid: 4886056 doi: 10.1155/2016/5065703

Garcia-Collinot G, Madrigal-Santillan EO, Martinez-Bencomo MA, Carranza-Muleiro RA, Jara LJ, Vera-Lastra O, et al. Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci. 2020;65(4):1134–43.

pubmed: 31549334 doi: 10.1007/s10620-019-05830-0

Soifer LO, Peralta D, Dima G, Besasso H. Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study. Acta Gastroenterol Latinoam. 2010;40(4):323–7.

pubmed: 21381407

Zakostelska Z, Malkova J, Klimesova K, Rossmann P, Hornova M, Novosadova I, et al. Intestinal microbiota promotes psoriasis-like skin inflammation by enhancing Th17 response. PLoS ONE. 2016;11(7): e0159539.

pubmed: 27434104 pmcid: 4951142 doi: 10.1371/journal.pone.0159539

Zanvit P, Konkel JE, Jiao X, Kasagi S, Zhang D, Wu R, et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. Nat Commun. 2015;6:8424.

pubmed: 26416167 doi: 10.1038/ncomms9424

Zhang M, Jiang Z, Li D, Jiang D, Wu Y, Ren H, et al. Oral antibiotic treatment induces skin microbiota dysbiosis and influences wound healing. Microb Ecol. 2015;69(2):415–21.

pubmed: 25301498 doi: 10.1007/s00248-014-0504-4

Baba H, Masuyama A, Yoshimura C, Aoyama Y, Takano T, Ohki K. Oral intake of Lactobacillus helveticus-fermented milk whey decreased transepidermal water loss and prevented the onset of sodium dodecylsulfate-induced dermatitis in mice. Biosci Biotechnol Biochem. 2010;74(1):18–23.

pubmed: 20057148 doi: 10.1271/bbb.90370

Gueniche A, Benyacoub J, Philippe D, Bastien P, Kusy N, Breton L, et al. Lactobacillus paracasei CNCM I-2116 (ST11) inhibits substance P-induced skin inflammation and accelerates skin barrier function recovery in vitro. Eur J Dermatol. 2010;20(6):731–7.

pubmed: 20965806

Ogawa M, Saiki A, Matsui Y, Tsuchimoto N, Nakakita Y, Takata Y, et al. Effects of oral intake of heat-killed Lactobacillus brevis SBC8803 (SBL88) on dry skin conditions: A randomized, double-blind, placebo-controlled study. Exp Ther Med. 2016;12(6):3863–72.

pubmed: 28105118 pmcid: 5228549 doi: 10.3892/etm.2016.3862

Kozakova H, Schwarzer M, Tuckova L, Srutkova D, Czarnowska E, Rosiak I, et al. Colonization of germ-free mice with a mixture of three lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell Mol Immunol. 2016;13(2):251–62.

pubmed: 25942514 doi: 10.1038/cmi.2015.09

Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J, et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS ONE. 2011;6(11): e27961.

pubmed: 22132181 pmcid: 3222668 doi: 10.1371/journal.pone.0027961

Jenneck C, Novak N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag. 2007;3(3):411–20.

pubmed: 18488075 pmcid: 2386357

Dai C, Jiang M, Sun MJ. Letter: increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than IBD. Aliment Pharmacol Ther. 2019;50(7):834–5.

pubmed: 31532556 doi: 10.1111/apt.15460

Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008;2(1):115–24.

pubmed: 19707434 pmcid: 2727775

Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–40.

pubmed: 20580412 doi: 10.1016/j.semarthrit.2010.04.003

Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13(1):15–9.

pubmed: 23777821 doi: 10.1016/j.autrev.2013.06.005

Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a Prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–40.

pubmed: 26053050 doi: 10.1038/jid.2015.208

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

pubmed: 30772098 doi: 10.1016/j.jaad.2018.11.057

Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4): e12946.

pubmed: 32697374

Naik PP. Adverse effects of anti-interleukin-23 agents employed in patients with psoriasis: a systematic review. Dermatology. 2022;238(5):886–96.

pubmed: 35697004 doi: 10.1159/000524199

Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, et al. Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial. J Invest Dermatol. 2018;138(9):1973–81.

pubmed: 29559344 doi: 10.1016/j.jid.2018.03.1501

Dei-Cas I, Giliberto F, Luce L, Dopazo H, Penas-Steinhardt A. Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index. Sci Rep. 2020;10(1):12754.

pubmed: 32728075 pmcid: 7391695 doi: 10.1038/s41598-020-69537-3

Koike Y, Kuwatsuka S, Nishimoto K, Motooka D, Murota H. Skin mycobiome of psoriasis patients is retained during treatment with TNF and IL-17 inhibitors. Int J Mol Sci. 2020;21(11):3892.

pubmed: 32486022 pmcid: 7312082 doi: 10.3390/ijms21113892

Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357(9262):1076–9.

pubmed: 11297958 doi: 10.1016/S0140-6736(00)04259-8

Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics—a review. J Food Sci Technol. 2015;52(12):7577–87.

pubmed: 26604335 pmcid: 4648921 doi: 10.1007/s13197-015-1921-1

Volkova LA, Khalif IL, Kabanova IN. Impact of the impaired intestinal microflora on the course of acne vulgaris. Klin Med (Mosk). 2001;79(6):39–41.

pubmed: 11525176

Ogawa M, Saiki A, Matsui Y, Tsuchimoto N, Nakakita Y, Takata Y, et al. Effects of oral intake of heat-killed Lactobacillus brevis SBC8803 (SBL88™) on dry skin conditions: a randomized, double-blind, placebo-controlled study. Exp Ther Med. 2016;12(6):3863–72.

pubmed: 28105118 pmcid: 5228549 doi: 10.3892/etm.2016.3862

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Tria. Retrieved from http://ir.evelobio.com/newsreleases/news-releasedetails/evelo-biosciencesreports-positive-edp1815 - interim-clinical-data. 2019.

Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–39.

pubmed: 23842110 pmcid: 3744517 doi: 10.4161/gmic.25487

Navarro-Lopez V, Martinez-Andres A, Ramirez-Bosca A, Ruzafa-Costas B, Nunez-Delegido E, Carrion-Gutierrez MA, et al. Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: a randomized controlled clinical trial. Acta Derm Venereol. 2019;99(12):1078–84.

pubmed: 31453631

Kragsnaes MS, Kjeldsen J, Horn HC, Munk HL, Pedersen FM, Holt HM, et al. Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open. 2018;8(4): e019231.

pubmed: 29703851 pmcid: 5922473 doi: 10.1136/bmjopen-2017-019231

Yin G, Li JF, Sun YF, Ding X, Zeng JQ, Zhang T, et al. Fecal microbiota transplantation as a novel therapy for severe psoriasis. Zhonghua Nei Ke Za Zhi. 2019;58(10):782–5.

pubmed: 31594178

Oh J, Byrd AL, Park M, Kong HH, Segre JA, Program NCS. Temporal stability of the human skin microbiome. Cell. 2016;165(4):854–66.

pubmed: 27153496 pmcid: 4860256 doi: 10.1016/j.cell.2016.04.008

Callewaert C, Knödlseder N, Karoglan A, Güell M, Paetzold B. Skin microbiome transplantation and manipulation: Current state of the art. Comput Struct Biotechnol J. 2021;19:624–31.

pubmed: 33510866 pmcid: 7806958 doi: 10.1016/j.csbj.2021.01.001

Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–20.

pubmed: 11422182 doi: 10.1046/j.1365-2230.2001.00832.x

Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease—a systematic review and meta-analysis. J Crohns Colitis. 2020;14(3):351–60.

pubmed: 31504363 doi: 10.1093/ecco-jcc/jjz152

Coufal S, Galanova N, Bajer L, Gajdarova Z, Schierova D, Jiraskova Zakostelska Z, et al. Inflammatory bowel disease types differ in markers of inflammation, gut barrier and in specific anti-bacterial response. Cells. 2019;8(7):719.

pubmed: 31337064 pmcid: 6678638 doi: 10.3390/cells8070719

Schierova D, Roubalova R, Kolar M, Stehlikova Z, Rob F, Jackova Z, et al. Fecal microbiome changes and specific anti-bacterial response in patients with IBD during anti-TNF therapy. Cells. 2021;10(11):3188.

pubmed: 34831411 pmcid: 8617723 doi: 10.3390/cells10113188

Tang H, Jin X, Li Y, Jiang H, Tang X, Yang X, et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet. 2014;46(1):45–50.

pubmed: 24212883 doi: 10.1038/ng.2827

Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011;7(8): e1002254.

pubmed: 21852963 pmcid: 3154137 doi: 10.1371/journal.pgen.1002254

Eppinga H, Poortinga S, Thio HB, Nijsten TEC, Nuij V, van der Woude CJ, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(10):1783–9.

pubmed: 28617755 doi: 10.1097/MIB.0000000000001169

Triantafillidis JK, Malgarinos G. Severe psoriasis preceding diagnosis of large bowel Crohn’s disease for 15 years. J Crohns Colitis. 2013;7(2): e80.

pubmed: 22883442 doi: 10.1016/j.crohns.2012.07.014

Juzlova K, Votrubova J, Dzambova M, Gopfertova D, Hercogova J, Smerhovsky Z. Gastrointestinal comorbidities in patients with psoriasis in the Czech Republic: The results of 189 patients with psoriasis and 378 controls. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(1):100–5.

pubmed: 26498213 doi: 10.5507/bp.2015.048

Lolli E, Saraceno R, Calabrese E, Ascolani M, Scarozza P, Chiricozzi A, et al. Psoriasis phenotype in inflammatory bowel disease: a case-control prospective study. J Crohns Colitis. 2015;9(9):699–707.

pubmed: 25908719 doi: 10.1093/ecco-jcc/jjv068

Nehring P, Przybyłkowski A. Is psoriasis treatment a risk factor for inflammatory bowel disease? Pharm Med. 2020;34:257–62.

doi: 10.1007/s40290-020-00340-1

Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckland, NZ). 2016;6:73.

Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohns Colitis. 2013;7(10):769–79.

pubmed: 23453887 doi: 10.1016/j.crohns.2013.01.009

Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13(1):15–9.

pubmed: 23777821 doi: 10.1016/j.autrev.2013.06.005

Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20(2):100–8.

pubmed: 18923992 doi: 10.1080/09546630802441234

Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Norgard BM. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(3):289–94.

pubmed: 31267570 doi: 10.1111/apt.15370

Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharm Ther. 2009;29(9):921–7.

doi: 10.1111/j.1365-2036.2009.03955.x

Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048–55.

pubmed: 20728573 doi: 10.1016/j.cgh.2010.07.022

Pugliese D, Guidi L, Ferraro PM, Marzo M, Felice C, Celleno L, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharm Ther. 2015;42(7):880–8.

doi: 10.1111/apt.13352

Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048–55.

pubmed: 20728573 doi: 10.1016/j.cgh.2010.07.022

Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996–1001.

pubmed: 18576309 doi: 10.1002/art.23835

Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2021;33(3):346–57.

pubmed: 32889976 doi: 10.1097/MEG.0000000000001917

Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthrit Rheum-Arthr. 2008;59(7):996–1001.

doi: 10.1002/art.23835

Gatzka M. Skin under Tnf influence: how regulatory T cells work against macrophages in psoriasis. J Pathol. 2017;241(1):3–5.

pubmed: 27747869 doi: 10.1002/path.4820

Jayasekera PSA, Walsh ML, Hurrell D, Parslew RAG. Case report of lichen planopilaris occurring in a pediatric patient receiving a tumor necrosis factor alpha inhibitor and a review of the literature. Pediatr Dermatol. 2016;33(2):E143–6.

pubmed: 26840781 doi: 10.1111/pde.12768

Andrade P, Lopes S, Albuquerque A, Osorio F, Pardal J, Macedo G. Oral lichen planus in IBD patients: a paradoxical adverse effect of anti-TNF-alpha therapy. Digest Dis Sci. 2015;60(9):2746–9.

pubmed: 25917051 doi: 10.1007/s10620-015-3680-2

Inoue-Nishimoto T, Hanafusa T, Igawa K, Azukizawa H, Yokomi A, Yokozeki H, et al. Possible association of anti-tumor necrosis factor-alpha antibody therapy with the development of scleroderma-like changes with lichen planus. Eur J Dermatol. 2015;25(5):513–5.

pubmed: 26242643 doi: 10.1684/ejd.2015.2631

Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheu. 2010;40(3):233–40.

doi: 10.1016/j.semarthrit.2010.04.003

Furue K, Ito T, Tsuji G, Kadono T, Nakahara T, Furue M. Autoimmunity and autoimmune co-morbidities in psoriasis. Immunology. 2018;154(1):21–7.

pubmed: 29315555 pmcid: 5904708 doi: 10.1111/imm.12891

Wlodarczyk M, Sobolewska A, Wojcik B, Loga K, Fichna J, Wisniewska-Jarosinska M. Correlations between skin lesions induced by anti-tumor necrosis factor-alpha and selected cytokines in Crohn’s disease patients. World J Gastroentero. 2014;20(22):7019–26.

doi: 10.3748/wjg.v20.i22.7019

Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–77.

pubmed: 23468464 doi: 10.1136/gutjnl-2012-302853

Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55(2):205–11.

pubmed: 16188921 pmcid: 1856500 doi: 10.1136/gut.2005.073817

Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res. 2012;304(1):15–22.

pubmed: 22065152 doi: 10.1007/s00403-011-1189-x

Fry L, Baker BS, Powles AV, Fahlen A, Engstrand L. Is chronic plaque psoriasis triggered by microbiota in the skin? Brit J Dermatol. 2013;169(1):47–52.

doi: 10.1111/bjd.12322

Kong HDH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–9.

pubmed: 22310478 pmcid: 3337431 doi: 10.1101/gr.131029.111

Dong J, Goldenberg G. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis. 2017;99(2):123–7.

pubmed: 28319618

Fauny M, Moulin D, D’Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–8.

pubmed: 32719044 doi: 10.1136/annrheumdis-2020-217927

Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14(4):217.

pubmed: 22838497 pmcid: 3580547 doi: 10.1186/ar3893

Elsner K, Holstein J, Hilke FJ, Blumenstock G, Walker B, Schmidt S, et al. Prevalence of candida species in psoriasis. Mycoses. 2022;65(2):247–54.

pubmed: 34787934 doi: 10.1111/myc.13399

Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111(11):1599–607.

pubmed: 27481309 doi: 10.1038/ajg.2016.298

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700.

pubmed: 22595313 doi: 10.1136/gutjnl-2011-301668

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441-8 e2.

pubmed: 28027825 doi: 10.1016/j.jaad.2016.10.027

Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H. Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162.

pubmed: 31488067 pmcid: 6727530 doi: 10.1186/s12876-019-1067-0

Nazarian A, Grin A, Wijeratne DT. Ixekizumab associated new-onset inflammatory bowel disease. ACG Case Rep J. 2020;7(2): e00316.

pubmed: 32440523 pmcid: 7209798 doi: 10.14309/crj.0000000000000316

Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis. 2008;14(Suppl 2):S4-5.

pubmed: 18816745 doi: 10.1002/ibd.20545

Earley H, Lennon G, Balfe A, Coffey JC, Winter DC, O’Connell PR. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Sci Rep. 2019;9(1):15683.

pubmed: 31666581 pmcid: 6821857 doi: 10.1038/s41598-019-51878-3

Zhang T, Li P, Wu X, Lu G, Marcella C, Ji X, et al. Alterations of Akkermansia muciniphila in the inflammatory bowel disease patients with washed microbiota transplantation. Appl Microbiol Biotechnol. 2020;104(23):10203–15.

pubmed: 33064186 doi: 10.1007/s00253-020-10948-7

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775–804.

pubmed: 31351884 doi: 10.1016/j.jaad.2019.04.042

Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–3.

pubmed: 35968665 doi: 10.1080/14712598.2022.2113872

Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Pagination

Subventions

Informations de copyright

Références

Auteurs

Zuzana Jiraskova Zakostelska (Z)

Zuzana Reiss (Z)

Helena Tlaskalova-Hogenova (H)

Filip Rob (F)

Classifications MeSH